OncoZenge
5.99 SEK
+1.87 %
Less than 1K followers
ONCOZ
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for OncoZenge
P/B
Median 2021-2025
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Share price (SEK) | - | 11.56 | 5.50 | 3.09 | 3.75 | 6.76 |
| Shares | 14.5 | 11.7 | 11.7 | 11.7 | 11.7 | 12.6 |
| Market cap | - | 135.4 | 64.4 | 36.2 | 43.9 | 85.5 |
| Enterprise value | - | 84.2 | - | - | - | - |
| EV/S | - | - | - | - | - | - |
| EV/EBITDA | - | neg. | - | - | - | - |
| EV/EBIT | - | neg. | - | - | - | - |
| P/E | - | neg. | neg. | neg. | neg. | neg. |
| P/B | - | 1.69 | 1.90 | 1.94 | 4.41 | 10.09 |
| P/S | - | - | - | - | - | 32.1 |
| Dividend yield | - | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 76.5 % | 94.2 % | 92.1 % | 91.6 % | 87.1 % | 34.7 % |
| Gearing ratio | 30.8 % | - | - | - | - | 88.5 % |